Angela Mastronuzzi: Our aim was to evaluate the feasibility of VEN plus Cy-Topo in children with relapsed/refractory neuroblastoma
Angela Mastronuzzi, Head of Neuro-Oncology Unit at the Bambino Gesù Children’s Hospital, shared on LinkedIn:
“Happy to share my team’s recently published paper with Nature Portfolio!
‘Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series’
The prognosis of relapsed/refractory (R/R) neuroblastoma (NB) is dismal, calling for new therapeutic strategies. Venetoclax (VEN) is a highly selective, potent, orally bioavailable, BCL-2 inhibitor small-molecule that showed a synergistic effect with cyclophosphamide and topotecan (Cy-Topo) in murine NB models. Our aim was to evaluate the feasibility of VEN plus Cy-Topo in children with relapsed/refractory neuroblastoma.
Special thanks for the support by the Italian Ministry of Health with Current Research funds.”
For the article click here.
Source: Angela Mastronuzzi/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023